Vifor Pharma comments on market speculations

News provided by Vifor Pharma Group
December 03, 2021 11:50 Korea Standard Time

ST. GALLEN, SWITZERLAND--(Business Wire / Korea Newswire) December 03, 2021 -- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Due to current market speculations, Vifor Pharma Group states the following:

Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions. Vifor Pharma is therefore regularly in discussions with other market participants and does not comment on them.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005818/en/

Website: http://www.viforpharma.com

Contact

Vifor Pharma Group
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73


Investor Rations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90

This is a news release distributed by Korea Newswire on behalf of this company.